UPDATE 2-Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash [Reuters (UK)]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Reuters
Amgen to buy Celgene's psoriasis drug Otezla for $13.4 billion in cash - Reuters 2 Min Read (Reuters) - Amgen Inc said on Monday it would buy Celgene Corp’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene. Bristol-Myers now expects the Celgene deal to close by 2019 end, pushing Celgene’s shares up 3% before the opening bell. Amgen shares, however, fell as some investors worried that the company was shelling out more-than-expected for the drug. The deal for Otezla and certain related assets and liabilities is valued at $11.2 billion, net of the present value of $2.2 billion in future cash tax benefits. Bristol-Myers in June offered to sell Otezla, with an analyst valui
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Stocks rocked after Fed's Powell talks tariff impact [FOX Business Network]FOX Business Network
- KRAS Inhibitors Market Research and Forecasts 2025-2030: Lumakras, Krazati, Dupert, Anfangning Drug Sales, Patent, Price & Clinical Trials Insights [Yahoo! Finance]Yahoo! Finance
- Pruritus Therapeutics Market Analysis and Forecast 2025-2034 | Biologics and JAK Inhibitors Drive Innovation in Pruritus Care, Offering Targeted Relief and Long-term Efficacy [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at UBS Group AG from $315.00 to $319.00. They now have a "neutral" rating on the stock.MarketBeat
- [Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US [Yahoo! Finance]Corrected
AMGN
Earnings
- 2/4/25 - Beat
AMGN
Sec Filings
- 4/16/25 - Form PX14A6G
- 4/9/25 - Form DEFA14A
- 4/9/25 - Form DEF
- AMGN's page on the SEC website